Daily BriefsECM

Daily Brief ECM: Timee Pre-IPO – The Positives – Exponential Growth Since Inception and more

In today’s briefing:

  • Timee Pre-IPO – The Positives – Exponential Growth Since Inception
  • Sanil Electric IPO – Strong Profitability Growth, but Highly Dependent on Its Top Customers
  • Mexican Airlines – Capacity Management to Drive Bumper 2024; Gains Beyond Difficult
  • Pre-IPO Bayzed Health Group – Here Are the Concerns and Potential Risks


Timee Pre-IPO – The Positives – Exponential Growth Since Inception

By Clarence Chu

  • Timee Inc (215A JP) is looking to raise US$290m from its Japan IPO. The IPO will be a 100% secondary selldown by existing shareholders.
  • Timee operates an on-demand staffing platform that connects part-time jobseekers with businesses in Japan.
  • In this note, we will talk about the positive aspects of the deal.

Sanil Electric IPO – Strong Profitability Growth, but Highly Dependent on Its Top Customers

By Ethan Aw

  • Sanil Electric (062040 KS) is looking to raise up to US$164m in its Korean IPO.
  • Sanil Electric is a specialized company that manufactures and sells reactors, transformers, railway vehicle parts, and switchboards.  As an industrial transformer manufacturer, the company mainly manufactures power and distribution transformers.
  • In this note, we talk about the company’s historical performance.

Mexican Airlines – Capacity Management to Drive Bumper 2024; Gains Beyond Difficult

By Neil Glynn

  • We update forecasts for Mexican carriers Aeromexico, Viva Aerobus and Volaris following extremely strong 1Q results, driven by capacity management.
  • We expect each carrier to produce record performances in 2024 as pricing gains continue through the year.
  • However, we expect market conditions to normalise beyond 2024 and see further gains as a lot more difficult, particularly given drag from higher aircraft ownership costs.

Pre-IPO Bayzed Health Group – Here Are the Concerns and Potential Risks

By Xinyao (Criss) Wang

  • Bayzed’s business model is similar to that of Hygeia and Inkon Life Technology. However, Bayzed’s profit margin is largely lagging behind peers. This makes us concerned about its future profitability.
  • The nationwide expansion of oncology hospitals is very challenging. Bayzed’s expansion pace may not be as fast as expected if it hopes to control the quality of expansion.
  • Due to “heavy asset” model, Bayzed would continue to face capital pressure.The latest valuation of Bayzed in 2023 is RMB2.625 billion. We think Bayzed’s valuation should be lower than peers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars